SHANDONG WOHUA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.51 CNY | +0.45% |
|
-7.39% | -25.70% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,385 | 3,084 | 4,641 | 4,271 | 3,579 | 3,504 |
| Enterprise Value (EV) 1 | 2,062 | 2,784 | 4,335 | 3,945 | 3,302 | 3,103 |
| P/E ratio | 50.8 x | 31.7 x | 25.9 x | 26.4 x | 32.6 x | 60.7 x |
| Yield | 0.76% | 1.4% | 3.23% | 3.51% | - | 4.12% |
| Capitalization / Revenue | 3.08 x | 3.59 x | 4.61 x | 4.53 x | 3.53 x | 3.85 x |
| EV / Revenue | 2.66 x | 3.24 x | 4.31 x | 4.18 x | 3.25 x | 3.41 x |
| EV / EBITDA | 30.8 x | 23.2 x | 18.6 x | 17.5 x | 24.1 x | 39 x |
| EV / FCF | 507 x | -92 x | 30.9 x | 37.2 x | 23 x | 27.2 x |
| FCF Yield | 0.2% | -1.09% | 3.24% | 2.69% | 4.35% | 3.68% |
| Price to Book | 4.01 x | 4.59 x | 5.75 x | 5.2 x | 4.79 x | 4.35 x |
| Nbr of stocks (in thousands) | 577,210 | 577,210 | 577,210 | 577,210 | 577,210 | 577,210 |
| Reference price 2 | 4.131 | 5.344 | 8.040 | 7.400 | 6.200 | 6.070 |
| Announcement Date | 1/31/19 | 4/28/20 | 1/20/21 | 1/20/22 | 3/22/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 774.4 | 860.3 | 1,006 | 942.7 | 1,015 | 909.5 |
| EBITDA 1 | 66.9 | 120 | 233.6 | 225 | 136.8 | 79.57 |
| EBIT 1 | 48.11 | 101.5 | 205.5 | 192 | 101.8 | 47.05 |
| Operating Margin | 6.21% | 11.8% | 20.43% | 20.36% | 10.03% | 5.17% |
| Earnings before Tax (EBT) 1 | 43.6 | 112.9 | 220.5 | 190 | 110.8 | 54.64 |
| Net income 1 | 45.65 | 95.8 | 178.9 | 163.4 | 107.4 | 58.77 |
| Net margin | 5.89% | 11.14% | 17.78% | 17.33% | 10.58% | 6.46% |
| EPS 2 | 0.0813 | 0.1688 | 0.3100 | 0.2800 | 0.1900 | 0.1000 |
| Free Cash Flow 1 | 4.067 | -30.27 | 140.4 | 106 | 143.7 | 114.1 |
| FCF margin | 0.53% | -3.52% | 13.96% | 11.24% | 14.16% | 12.54% |
| FCF Conversion (EBITDA) | 6.08% | - | 60.12% | 47.09% | 105.03% | 143.34% |
| FCF Conversion (Net income) | 8.91% | - | 78.51% | 64.86% | 133.79% | 194.09% |
| Dividend per Share 2 | 0.0313 | 0.0750 | 0.2600 | 0.2600 | - | 0.2500 |
| Announcement Date | 1/31/19 | 4/28/20 | 1/20/21 | 1/20/22 | 3/22/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 323 | 301 | 306 | 327 | 277 | 401 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 4.07 | -30.3 | 140 | 106 | 144 | 114 |
| ROE (net income / shareholders' equity) | 5.92% | 13.2% | 22% | 17.5% | 10.5% | 5.74% |
| ROA (Net income/ Total Assets) | 3.38% | 6.57% | 10.8% | 9.48% | 5.63% | 2.62% |
| Assets 1 | 1,350 | 1,457 | 1,656 | 1,723 | 1,908 | 2,243 |
| Book Value Per Share 2 | 1.030 | 1.160 | 1.400 | 1.420 | 1.290 | 1.400 |
| Cash Flow per Share 2 | 0.5600 | 0.5200 | 0.8600 | 0.5700 | 0.4800 | 0.6900 |
| Capex 1 | 63.1 | 32.2 | 54.2 | 19.1 | 6.77 | 2.72 |
| Capex / Sales | 8.15% | 3.75% | 5.38% | 2.02% | 0.67% | 0.3% |
| Announcement Date | 1/31/19 | 4/28/20 | 1/20/21 | 1/20/22 | 3/22/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -25.70% | 358M | |
| +39.50% | 6.23B | |
| +5.32% | 3.32B | |
| -18.39% | 2.91B | |
| -6.41% | 2.42B | |
| +42.43% | 1.94B | |
| -14.15% | 1.59B | |
| -4.27% | 1.58B | |
| +38.37% | 1.49B | |
| -15.57% | 1.48B |
- Stock Market
- Equities
- 002107 Stock
- Financials Shandong Wohua Pharmaceutical Co., Ltd.
